Want to see TTRX full AI Analyst Report?
TTRX Stock Chart & Stats
$2.74
--
Market closed
$2.74
--
Day’s Range― - ―
52-Week Range$2.57 - $26.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.86M
Market Cap
$212.09M
Enterprise Value$174.41M
Total Cash (Recent Filing)$11.22M
Total Debt (Recent Filing)$6.01M
Price to Earnings (P/E)―
Beta-0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,788,040
10 Day Avg. Volume2,856,380
30 Day Avg. Volume2,856,380
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.12K
Enterprise Value/Ebitda-45.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & Safety (GX-03)Robust interim Phase 2 efficacy and clean safety materially de-risks the lead program versus many early-stage dermatology candidates. Sustained responder rates and tolerability support faster regulatory discussions, partner interest, and a clearer path to pivotal design choices that affect long-term commercial opportunity.
Regulatory & Clinical LeadershipHiring a former FDA Commissioner strengthens regulatory strategy and credibility with regulators and potential partners. That institutional expertise can improve trial design, accelerate regulatory interactions, and reduce approval execution risk—durable advantages through late-stage development and launch planning.
Balance-sheet Recapitalization & Low DebtA meaningful asset increase and restored positive equity materially improve financial flexibility relative to prior periods. Low absolute debt reduces solvency risk and gives management time to execute clinical milestones before large refinancing, supporting runway extension and partnership leverage over the medium term.
Bears Say
Pre-revenue & Widening LossesThe company remains pre-revenue and posted a materially larger operating loss in 2025, reflecting rising R&D and G&A spend without commercial offset. This structural lack of internal cash generation keeps the business dependent on external financing until commercialization, increasing execution and dilution risk.
Accelerating Negative Cash FlowOperating and free cash flow deterioration in 2025 signals an accelerating burn rate that shortens runway absent new funding. For a development-stage biotech, rising cash outflows elevate the probability of near-term financings and can force trade-offs between program prioritization and timely trial progression.
Financing Dependence With Costly TermsReliance on a secured debt facility that is costly creates structural constraints: higher financing expense, potential lien or covenant restrictions, and limited optionality versus equity raises. This reduces strategic flexibility and raises the stakes on upcoming clinical readouts to avoid onerous refinancing or dilutive raises.
Turn Therapeutics Inc News
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $26.50 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $212.09M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Turn Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Overvalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 29,788,040 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Currently, no hedge funds are holding shares in TTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Turn Therapeutics Inc
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Pulmatrix
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
59.05% Insiders
0.23% Mutual Funds
0.71% Other Institutional Investors
39.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---